BlueCrest Capital Management’s Celldex Therapeutics CLDX Stock Holding History

BlueCrest Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-14,213	Closed	-$96K	–	942
2018 Q3	$96K	Buy	14,213 +1,325	+10%	+$9.28K	﹤0.01%	1390
2018 Q2	$97K	Buy	12,888 +5,265	+69%	+$70.4K	﹤0.01%	1397
2018 Q1	$266K	Buy	+7,623	New	+$295K	0.01%	1131
2017 Q4	–	Sell	-6,029	Closed	-$259K	–	862
2017 Q3	$259K	Buy	6,029 +1,778	+42%	+$66.7K	0.01%	671
2017 Q2	$158K	Buy	+4,251	New	+$188K	0.01%	780
2015 Q4	–	Sell	-1,879	Closed	-$297K	–	997
2015 Q3	$297K	Buy	+1,879	New	+$532K	0.01%	705

Other funds holding CLDX

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlueCrest Capital Management's CLDX Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Celldex Therapeutics (CLDX) in Q4 2018, closing a stake of 14,213 shares — an estimated $96K sold.

BlueCrest Capital Management first reported a position in CLDX in Q3 2015 and held it in 6 quarters. The position peaked at $297K in Q3 2015. 85 funds tracked by Wall St. Rank hold CLDX as of Q4 2018.

BlueCrest Capital Management reported no remaining Celldex Therapeutics position as of Q4 2018 after selling out during the quarter.
BlueCrest Capital Management sold 14,213 Celldex Therapeutics shares in Q4 2018, an estimated $96K.
BlueCrest Capital Management first reported a position in Celldex Therapeutics in Q3 2015 and held it in 6 quarters.
BlueCrest Capital Management's Celldex Therapeutics position peaked at $297K in Q3 2015.
85 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.